NATCO records INR 2,022.4 Crore consolidated revenue and INR 458.1 Crore of PAT for the full year ended March 2020

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 2,022.4 Crore for the year ended on 31st March, 2020, as against INR 2224.7 Crore for the last year, reflecting a decline of around 9%, year-over-year. The net profit for the period, on a consolidated basis, was INR 458.1 Crore, as against INR 642.4 Crore last year, showing a decline of about 29%.

For the fourth quarter (Q4) ended March 31st, 2020, the company recorded a net revenue of INR 477.2 Crore, on a consolidated basis, as against INR 486.7 Crore during Q4, FY 2019. The profit after tax, on a consolidated basis, was recorded as INR 93.2 Crore for the quarter, as against INR 120.4 Crore same quarter last year.

The overall decline in revenue and profits, from prior year, was primarily due to continued decline in Hepatitis C product portfolio and to an extent in oncology segment due to pricing pressures. The company also faced slowdown in business operations during the fourth quarter due to supply chain issues amidst Covid-19 concerns, which were subsequently resolved.

The Board of Directors has recommended a fourth interim dividend of INR 1.00 per equity share of INR 2/- each, resulting in a total dividend payout of INR 6.75 per equity share for the year.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.639.2 as compared to the previous close of Rs. 604.8. The total number of shares traded during the day was 24225 in over 2043 trades.

The stock hit an intraday high of Rs. 643.55 and intraday low of 612. The net turnover during the day was Rs. 15296932.

Source : Equity Bulls

Keywords